2144 results about "Insulin humulin" patented technology

A blood glucose sensing system includes a plurality of physiological sensors. The system can estimate blood glucose based on discrete invasive blood glucose estimates from a blood sample, discrete noninvasive blood glucose estimates derived from optical sensors, and continuously-calculated blood glucose estimates derived from a nonlinear state-space model of glucose and insulin reactions within a human body. The state-space model has user-entered values corresponding to their insulin and meal intake. The user's blood glucose is estimated from a combination of the discrete invasive blood glucose estimates, the discrete noninvasive blood glucose estimates and the continuously-calculated blood glucose estimate.

Embodiments of the present disclosure provide insulin formulations having a near neutral pH and improved pharmacokinetic / pharmacodynamic properties, and uses in insulin infusion devices that may provide extended infusion period up to 7-14 days. Also provided are systems for administering insulin, the system may include a first reservoir, a second reservoir, an insulin pump configured to administer contents of the first reservoir or the second reservoir, and one or more hardware processors in communication with the insulin pump.

The invention discloses an insulin infusion decision-making system and method combining reinforcement learning and metabolism simulation, and belongs to the field of clinical decision-making assistance. Comprising an acquisition processing module, a metabolism simulation module, a dynamic updating module, a path simulation module, a strategy control module, a monitoring constraint module, a decision analysis module, a correction processing module, a training optimization module and an injection control module. The method can accurately reflect the metabolic characteristics of the patient, makes the insulin decision more targeted, realizes automatic adjustment of the model, keeps real-time perception and response to the state of the patient, avoids the risk caused by model aging or error accumulation, enhances the long-term control ability, improves the control efficiency while guaranteeing the blood glucose stability, and reduces the cost. The fault-tolerant capability of the system is improved, the interpretability and safety guarantee of clinical decisions are improved, and the credibility of doctors is enhanced.

Techniques disclosed herein relate to nutritional content determination based on gesture detection data. In some embodiments, the techniques involve obtaining gesture detection data corresponding to consumption of a food item or a drink; determining, based on the gesture detection data, nutritional content of the food item or the drink; and causing delivery of insulin in accordance with the nutritional content of the food item or the drink.

The invention discloses a dynamic blood glucose monitoring and intelligent pump speed adjusting system and method, and relates to the technical field of biomedical engineering.The dynamic blood glucose monitoring and intelligent pump speed adjusting method comprises the steps that precise monitoring is conducted through a multi-mode sensing module, an enzyme electrode sensor adopts an anti-interference coating, a Raman spectrum dynamic correction algorithm is combined, and motion artifacts and temperature drift are restrained; the metabolic feature fusion calibration module is integrated with a time convolution network, time sequence modeling is carried out on diet, exercise and historical blood glucose data, an individualized metabolic parameter database is constructed, and self-adaptive signal drift compensation is achieved; the self-adaptive pump control module innovatively designs a double-layer fuzzy PID controller, a base layer generates an infusion rate according to a real-time blood glucose state and insulin activity, an optimization layer introduces an LSTM metabolism prediction model, and the slope of an infusion curve is dynamically adjusted in combination with future behavior pre-judgment; in the edge-cloud collaborative architecture, a lightweight TCN model is locally deployed to guarantee real-time control, and a cloud end optimizes a global digital twinborn model through federal learning and generates a multi-dimensional metabolic risk early warning report.

The invention relates to an integrated management system for diabetic patients, which comprises the following steps of: constructing a high-dimensional metabolic data model, performing multi-modal fusion on genome information, metabolome data and life behavior data, and mining a potential mode of metabolic characteristics of the patients; carrying out patient typing by utilizing a clustering algorithm comprising a self-organizing mapping network, and identifying different metabolism types comprising an insulin resistance type and an insulin secretion insufficiency type; developing a hierarchical management strategy based on a typing result, wherein the hierarchical management strategy comprises diet, exercise and medicine intervention schemes for different types; collecting dynamic quantitative indexes of the metabolic load, and integrating the blood glucose fluctuation amplitude, insulin sensitivity and daily nutrition intake of the patient; constructing a metabolic load prediction model, and combining a time sequence deep learning algorithm with real-time data, including blood glucose, diet and exercise, of a patient to measure a future metabolic load; and establishing a causal relationship model between patient behaviors and metabolic reactions, and analyzing an interaction mode of diet, exercise and metabolic loads by adopting a causal inference technology.

The invention relates to the technical field of medical equipment, in particular to application equipment for treating diabetes mellitus, which is good in use effect and comprises a shell and a placing shell. By arranging an electric telescopic rod, a movable plate, a detection needle and a blood glucose detector, before insulin injection, the movable plate is pulled through the electric telescopic rod, at the moment, a vertical rod moves in a triangular groove, the detection needle is inserted into the skin of a patient, then the blood of the patient is detected, and the blood glucose detector is used for detecting the insulin. The real-time blood glucose condition of the patient can be detected, and the blood glucose detection function of the patient is achieved; by arranging an electric telescopic rod and a movable plate, when the device is not used, the movable plate is moved to the center position opposite to the fixed plate through the electric telescopic rod, at the moment, a treatment needle and a detection needle are both located in an inner cavity of the shell, discomfort caused when a needle head is inserted into the skin for a long time is avoided, and the use effect is good. The device has the advantages of being good in use effect and diversified in function.

The invention discloses a glucose response type insulin delivery system as well as a preparation method and application thereof, and belongs to the technical field of biological materials. The glucose response type insulin delivery system provided by the invention comprises a delivery carrier and a bioactive component encapsulated in the carrier, the delivery carrier is a metal polyphenol network formed by carrying out coordination reaction on epigallocatechin gallate and metal ions; the bioactive components comprise glucose oxidase, catalase and insulin. The glucose response type insulin delivery system provided by the invention can adjust the release of insulin according to the concentration of glucose in the surrounding environment, so that the blood glucose is maintained at a normal level.

The invention relates to application of fermentation lactobacillus mucus LFPerfectuus001 in preparation of a product for improving metabolic syndrome caused by high-fat and high-sugar diet, and belongs to the technical field of microorganisms. The invention provides application of fermented lactobacillus mucus LFPerfecus001 in preparation of a product for improving metabolic syndrome, the fermented lactobacillus mucus LFPerfecus001 is preserved in Guangdong Microbial Culture Collection Center on April 13, 2022, and the preservation number is GDMCC No: 62335. The invention further provides a preparation method of the fermented lactobacillus mucus LFPerfecus001. Animal experiments report that the fermented lactobacillus mucus LFPerfectus001 has the effects of reducing fat, increasing muscle, improving obesity, hyperglycemia, insulin resistance, dyslipidemia, hyperuricemia and fatty liver for the first time, and can well improve metabolic syndrome caused by high fat and high glucose.

The invention provides an exosome, a mesenchymal stem cell and application of the exosome and the mesenchymal stem cell in treatment of type 2 diabetes mellitus, and belongs to the technical field of biological medicine. The exosome secreted by the umbilical cord mesenchymal stem cells of the composite pretreatment group is used for treating the type 2 diabetes mellitus, and the obvious advantages are shown. Compared with a model control group, the exosome has the advantages that the glucose tolerance of diabetic rats treated by the exosome is obviously improved, the blood glucose value is reduced by about 47.5% within 120 minutes, the area under a blood glucose curve (AUC) is reduced by about 50.5%, the serum insulin is increased by about 147.7%, insulin secretion is effectively promoted, the glycosylated hemoglobin level is obviously reduced, and the long-term blood glucose control effect is good. By integrating various indexes, the exosome obtained by the composite pretreatment scheme provided by the invention has a remarkable effect of improving the illness state of rats with type 2 diabetes mellitus, provides a new effective strategy for treatment of type 2 diabetes mellitus, and shows a good application prospect.

The invention discloses a blood glucose concentration prediction method combined with a neural network, and relates to the technical field of blood glucose concentration prediction.The method comprises the steps that continuous blood glucose monitoring equipment interacts with a target user to conduct blood glucose monitoring, and a dynamic blood glucose concentration sequence in a preset monitoring window is extracted; acquiring an exercise data set, a food intake data set, an insulin use record set and an environment monitoring data set of the target user in the preset monitoring window; obtaining a blood glucose data topological framework sequence; obtaining a blood glucose feature recognition model; performing cross-scale mapping interaction analysis to obtain blood glucose associated features; training a blood glucose concentration prediction network layer; and performing blood sugar concentration prediction on the blood sugar related characteristics to obtain a blood sugar concentration prediction result. The technical problem that in the prior art, blood glucose concentration prediction is conducted in a single dimension, and the accuracy of the prediction result is low is solved, and the technical effect of improving the accuracy and timeliness of blood glucose concentration prediction is achieved.

The invention relates to a device control method, an insulin infusion device and a storage medium. The method is applied to insulin infusion equipment, and the insulin infusion equipment comprises a driving mechanism and a pushing injection mechanism. The equipment control method comprises the steps of determining a current operation mode executed by the insulin infusion equipment, determining whether current input belongs to forbidden operation of a safe operation rule according to the safe operation rule of the current operation mode when the current input of a user to a function icon is monitored in the current operation mode, and if the current input belongs to the forbidden operation, executing the insulin infusion equipment according to the forbidden operation. If the current input belongs to the prohibition operation, the insulin infusion device is controlled not to respond to the current input, and if the current input does not belong to the prohibition operation, the insulin infusion device is controlled to respond to the current input to execute a corresponding instruction so as to control the driving mechanism to push the injection mechanism, and infusion of the insulin infusion device is achieved. By adopting the method, the safety of insulin infusion equipment can be improved.

The invention discloses an insulin resistance early detection method, system, equipment and medium, and the method comprises the following steps: screening an obtained insulin resistance potential factor and an insulin resistance result corresponding to a first to-be-detected sample individual to obtain a key detection factor; different to-be-screened neural network models are evaluated to determine a to-be-optimized detection model, and the evaluation process is designed to perform screening according to feedback of the different to-be-screened neural network models in clinical prediction. And based on the key detection factor and the insulin resistance result, carrying out interpretability analysis on the to-be-optimized detection model to obtain a target insulin resistance detection model, and applying the target insulin resistance detection model to actual insulin resistance early detection. The method provided by the invention is low in detection cost, simple in operation steps and high in detection accuracy, and the insulin resistance risk is identified in an early stage by analyzing conventional physical examination data.

The invention relates to the technical field of medical instruments, in particular to a hypodermic injection device which comprises a pen body, an insulin refill detachably connected to the bottom of the pen body, and a disposable pen needle matched with the bottom of the insulin refill. The push rod is movably arranged in the pen body, and the bottom end of the push rod is used for pushing liquid medicine in the insulin refill; a labor-saving assembly is mounted in the pen body; the labor-saving assembly comprises a first wedge-shaped block fixedly connected to the top of the push rod, a transmission sliding groove formed in the inner side of the pen body, a transmission sliding block slidably connected to the interior of the transmission sliding groove, a transmission rolling wheel rotationally connected to one end of the transmission sliding block and a second wedge-shaped block arranged in the pen body and capable of vertically moving. According to the invention, the inclined surfaces of the 60-degree wedge-shaped block I and the 30-degree wedge-shaped block II are matched, and the force conduction of the transmission roller is combined, so that the vertical thrust of the injection driving mechanism is amplified into horizontal thrust, the operation force is reduced by more than 70%, the thrust in the whole injection process is ensured to be stable, and pains and errors are relieved.

The invention discloses a personalized medical health service recommendation system based on big data analysis, and belongs to the technical field of medical health services. The synchronization module is used for generating a standardized data stream according to dynamic blood glucose monitoring data and an original heart rate variability signal; the analysis module is used for generating a diet time sequence data stream according to the intake event timestamp; the blood glucose feature extraction module is used for extracting data from the standardized data stream; the insulin sensitivity analysis module is used for generating an insulin sensitivity factor matrix; the nutrition analysis module is used for generating a carbohydrate equivalent time distribution vector and a dietary fiber intake intensity value; the feature fusion module is used for generating a fusion feature vector according to the blood glucose drift trend coefficient, the insulin sensitive factor matrix and the carbohydrate equivalent time distribution vector; the risk assessment module is used for generating a hypoglycemia risk probability value according to the fusion feature vector; and the recommendation generation module is used for generating a personalized service recommendation set according to the hypoglycemia risk probability value.

A method may include obtaining blood glucose level readings over a diurnal period for each of a plurality of days and determining an estimated variability of the blood glucose levels over the diurnal period for the plurality of days. The method may also include modifying, based on the estimated variability of the blood glucose level, a target blood glucose level to a modified target blood glucose level, and delivering insulin, using an insulin pump, during the diurnal period based on the modified target blood glucose level.

Provided is the use of a conjugated cholic acid, tryptophan-conjugated bile acids (TrpCA) or a TrpCA-producing strain for preventing and / or treating a metabolic disease. The present disclosure relates to the use of tryptophan-conjugated cholic acid or its producing bacteria strain in the preparation of a composition for preventing and / or treating a metabolic disease, or for promoting GLP-1 and / or insulin production. The inventors have discovered for the first time that the tryptophan-conjugated cholic acid can significantly promote the secretion of GLP-1 in both in vivo animal model and in vitro cell model, thereby reducing weight, lowering blood glucose and relieving symptoms of non-alcoholic fatty liver disease. Moreover, colonization of the selected probiotics can also have the same metabolic improvement effects.

In an infusion pump system that includes a pump that may have a user interface for pump programming, one or more smartphones or other remote control devices that interface with the infusion pump, and / or an automated insulin delivery algorithm, there is a potential conflict between commands such as boluses being programmed on multiple devices and / or calculated by the AID algorithm at the same time. In order to avoid low glucose levels that could result from delivering multiple boluses from these various sources when only one bolus is needed, systems and methods disclosed herein provide a bolus permissions and prioritization scheme that prioritizes boluses programmed with the infusion pump and one or more remote control devices and calculated by a closed loop delivery algorithm.

There is provided the use of Lactobacillus paracasei or a afterbiogen in the preparation of a pharmaceutical composition or a food composition for the production of tryptophan-binding cholic acid. The Lactobacillus paracasei or the afterbiogen thereof can be used to prevent and / or treat metabolic diseases or to promote the production of GLP-1 and / or insulin, or to maintain blood glucose healthy levels, to maintain blood lipid health and / or to control fat in the body.

The invention provides application of combined cholic acid TrpCA and producing bacteria thereof in treating and preventing metabolic diseases. The present invention relates to the use of tryptophan-binding cholic acid or a producing bacterium thereof in the preparation of a composition for preventing and / or treating a metabolic disease or for promoting the production of GLP-1 and / or insulin. The inventor finds for the first time that tryptophan-bound cholic acid can remarkably promote secretion of GLP-1 on an in-vivo animal model and an in-vitro cell model, the effects of reducing weight, reducing blood sugar and relieving the symptoms of the non-alcoholic fatty liver disease are achieved, and the same metabolism improvement effect can also be achieved through planting of probiotics capable of generating cholic acid TrpCA.

In some examples, a system includes a glucose sensor configured to generate a signal indicative of a blood glucose level of a patient, a medical device configured to deliver insulin to the patient, a peritoneal dialysis (PD) device, and control circuitry. The control circuitry is configured to control the PD device to deliver PD therapy to a patient during a PD cycle, determine a blood glucose level of the patient during the PD cycle based on a signal from the glucose sensor, determine that the blood glucose level is greater than or equal to a predetermined blood glucose level threshold, and control the medical device to deliver insulin to the patient in response to determining the blood glucose level is greater than or equal to the predetermined blood glucose level threshold.

The invention discloses a portable wound surface protection brace and an application method thereof, and belongs to the technical field of medical instruments. The brace is of a cylindrical structure, is made of EVA materials, has flexibility, non-toxic characteristics and good supporting performance and is externally wrapped with cotton cloth and provided with ventilation through holes, high-density cotton strips are fixed to the two ends of the inner wall to form a hollow structure, and the circumference of the outer wall can be adjusted through at least three sets of bandages with hook-and-loop fasteners. And an antibacterial coating is added, so that clinical application is expanded. During application, a wound surface is subjected to liquid extraction and hydrogen peroxide cleaning in the earlier stage and then covered with insulin mixed normal saline gauze, and the dressing is prevented from making contact with clothes in cooperation with a brace; and smearing mupirocin ointment in the later stage and performing infrared irradiation, and continuously using the brace to keep the wound dry and zero contact. The brace can be repeatedly used, can adapt to various wound types and patient body types, effectively solves the problems of wound adhesion and friction in traditional nursing, creates a high-oxygen healing environment, remarkably shortens wound healing time, relieves pain of patients and improves life quality, and has good clinical application and popularization value.

A computer implemented method for determining a dosage of semaglutide for administering to a patient for the treatment of obesity, the method comprising: receiving patient data relating to a patient, wherein the patient data includes patient weight data; processing the patient data with a dosage calculator to determine the dosage of semaglutide for administering to the patient; and indicating the dosage.

The embodiments described herein may relate to methods and systems for adjusting insulin delivery. Some methods and systems may be configured to adjust insulin delivery to personalize automated insulin delivery for a person with diabetes. Such personalization may include receiving and / or determining one or more user specific dosage parameters.

The invention relates to the technical field of artificial intelligence, and discloses a blood glucose management system based on artificial intelligence. According to the system, blood glucose monitoring is reminded through the blood glucose monitoring terminal, a blood glucose curve is drawn every week, abnormal blood glucose conditions are judged for reminding and alarming, the diet terminal is used for guiding low-sugar diet recommendation, high-sugar food intake is avoided, the mastering degree of a patient and family members for food classification is improved, and the exercise terminal determines the exercise time and exercise amount of the patient according to the blood glucose value. Parameters are input into an intelligent system, the system converts and selects a motion mode, time and intensity, a drug treatment terminal calculates the insulin injection amount of a patient every day and every meal according to the blood glucose level and food intake, the insulin dosage is adjusted according to the calculated numerical values, blood glucose fluctuation is reduced, and the treatment effect is improved. The education and self-management terminal guides a patient to improve the cognitive degree of diabetes and provides personalized propaganda and education guidance for the patient, and the complication reminding terminal controls the blood sugar of the patient within a normal range, guides a good lifestyle of the patient and guides behavior specifications.

Disclosed are techniques to establish a modified pump rate that mitigates the effects of a pump occlusion and enables a recommended dosage of insulin to be output by a pump mechanism over the course of a control cycle. In an example, the pump rate may be reduced by adding a calculated time interval between application of actuation commands to extend the amount of time over which insulin may be output by the pump mechanism.

The invention provides an injection pen special for preventing acupuncture injury of insulin, and relates to the technical field of medical instruments, the injection pen comprises an injection pen body, the outer circumference of the injection pen body is provided with a metering observation window, the rear end face of the injection pen body is provided with an injection push key, and the front end face of the injection pen body is provided with a piston rod. The injection needle is sleeved with the inner needle cap and the outer needle cap, multiple protections are formed, it is ensured that the injection needle is properly protected in the transportation, storage and use processes, the probability of pricking injury is greatly reduced, the rubber column is fixedly installed at the front end of the outer needle cap, for old people with poor eyesight, a needle head can be inserted into the rubber column, and the rubber column is fixedly installed at the front end of the outer needle cap. The needle head can be hidden, and the problems that old people with poor eyesight are difficult to read metering scales, and a replaced injection needle is prone to hurting a user and other people are solved.

The invention provides a hypoglycemic peptide which is prepared by taking bovine whey protein as a raw material and is stable in gastrointestinal digestion and absorption. In an in-vitro cell experiment, the peptide fragment can improve the uptake of insulin-resistant HepG2 hepatocytes and synthesize glycogen by using glucose, can promote intestinal endocrine cells NCI-H716 to secrete GLP-1, has a certain synergistic effect, and can further play the effects of promoting GLP-1 secretion and activating a GLP-1 receptor through combined use. An insulin resistance mouse model is constructed by utilizing high-fat diet, and the peptide fragment is adopted for intervention, so that the hypoglycemic peptide is further proved to have obvious effects on losing weight, reducing lipid accumulation and assisting in reducing blood fat, and meanwhile, the hypoglycemic peptide can be used for improving insulin resistance related symptoms. The milk peptide provided by the invention has gastrointestinal digestion stability and hypoglycemic activity, can be used as a functional milk base material for developing food, medicines or health care products with the effect of regulating blood sugar, and is wide in application prospect.

The utility model relates to an insulin treatment cart. The insulin treatment cart comprises a frame; the operation table top is arranged at the top end of the frame and comprises a special injector box for placing an insulin injector, a special blood glucose testing box for placing related tools for testing blood glucose and a blood glucose meter placing frame for placing a blood glucose meter, and a sharp instrument box for conveniently recycling a needle head of the insulin injector is arranged in the special blood glucose testing box; the sharp instrument box comprises a box body and a box cover detachably arranged at the top of the box body, a dismounting hole is formed in the end face of the box cover, a dismounting ring is arranged in the dismounting hole, and a plurality of clamping blocks matched with the peripheral wall of a needle of the insulin syringe are arranged on the inner end face of the dismounting ring in the circumferential direction at intervals. And the drawer is arranged below the operation table top. Compared with the prior art, insulin for diabetes treatment and related tools can be placed in the insulin storage box in a standard mode, meanwhile, the insulin needle recycling box is arranged, medical workers are prevented from being punctured by needles, and the medical workers can conveniently find related articles and discard the needles after injection.

Some embodiments of an infusion pump system can be used to determine a user's total insulin load (TIL) that provides an accurate indication of the insulin previously delivered to the user's body which has not yet acted. In particular embodiments, the TIL can account for both the bolus deliveries and the basal deliveries that have occurred over a period of time. Such information may be useful, for example, when the infusion pump is operated in conjunction with a continuous glucose monitoring device.